Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P51114
UPID:
FXR1_HUMAN
Alternative names:
FMR1 autosomal homolog 1; hFXR1p
Alternative UPACC:
P51114; A8K9B8; Q7Z450; Q8N6R8
Background:
RNA-binding protein FXR1, also known as FMR1 autosomal homolog 1 or hFXR1p, plays a pivotal role in mRNA translation and stability. It is essential for neurogenesis, muscle development, and spermatogenesis, binding to AU-rich elements in the 3'-UTR of target mRNAs. FXR1 promotes the assembly of mRNAs into cytoplasmic ribonucleoprotein granules, facilitating the translation of specific transcripts, including MYC and CDKN1A mRNAs.
Therapeutic significance:
FXR1's involvement in congenital myopathies 9A and 9B, characterized by severe muscle weakness and developmental delays, underscores its therapeutic potential. Understanding the role of RNA-binding protein FXR1 could open doors to potential therapeutic strategies for these muscular disorders.